EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Integrated Clinical Genomic and Transcriptomic Subgrouping of Central Chondrosarcoma

Debora M Meijer, Sanne Venneker, Baptiste Ameline, Zeynep Erdem, Sara Cardoso, Dina Ruano, Inge H Briaire-de Bruijn, Brendy E van den Akker, Pauline M Wijers-Koster, Claire H J Scholte, Veroniek M van Praag, Michiel A J van de Sande und 4 weitere

Modern Pathology · 2025

DOI: 10.1016/j.modpat.2025.100894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2025. Verfasst von Debora M Meijer und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Leiden Center for Computational Oncology, Leiden University Medic…. Hauptthemen laut MEDLINE: Chondrosarcoma, Bone Neoplasms, Transcriptome, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw, Leiden University Medical Center, Kreftforeningen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Central conventional chondrosarcoma, a malignant cartilage-producing bone tumor, is the second most common bone sarcoma. Chondrosarcomas are histologically graded, which is so far the best predictor of survival. Early mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 genes are frequent, leading to the production of the oncometabolite D-2-hydroxyglutarate, which affects DNA methylation, resulting in a preferred chondrogenic differentiation over osteogenic differentiation of mesenchymal stem cells, which are currently considered the precursor cells of chondrosarcoma. DNA methylation profiling has previously revealed distinct profiles between IDH-mutant and IDH-wild-type chondrosarcomas, but the presence of further DNA methylation subgroups indicates that classification based solely on IDH status is too simplistic. In this study, we aim to identify biological subgroups in a total of 116 chondrosarcomas by integrating clinical data, IDH mutation status, gene expression, and genome-wide loss of heterozygosity (LOH). Clinical associations were observed between several factors, including sex and histological grade, as well as tumor site and IDH mutation status. RNA sequencing and genome-wide LOH confirmed the distinction between IDH-wild-type and IDH-mutant chondrosarcomas, where the number of chromosome arms affected by LOH was significantly higher in IDH-wild-type tumors than in IDH-mutant tumors. However, no clear subgroups emerged within each IDH group. Further clustering on RNA expression of differentiation markers identified subgroups characterized by chondrogenic, osteogenic, resting chondrocyte, or dedifferentiated profiles. These different subgroups showed a specific clinical presentation and suggest different precursor cells. Instead of a simple dichotomy between IDH-mutant and IDH-wild-type, our integrated approach highlights interconnected clinical, genomic, and transcriptomic patterns that offer a more nuanced view of chondrosarcoma biology and might potentially guide treatment stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChondrosarcomaBone NeoplasmsTranscriptomeBiomarkers, TumorHumansFemaleMaleIsocitrate DehydrogenaseMiddle AgedMutationAdultAgedLoss of HeterozygosityGene Expression ProfilingGenomicsYoung AdultDNA MethylationAdolescent

Stichwörter der Autor:innen

chondrosarcomagenome-wide loss of heterozygositysubgroupingtranscriptomics

Substanzen

Isocitrate DehydrogenaseIDH1 protein, humanIDH2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Leiden Center for Computational Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Bone Tumor Reference Center at the Institute of Medical Genetics and Pathology, University Hospital and University of Basel, Basel, Switzerland.
  • Department of Orthopaedic Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands; Leiden Center for Computational Oncology, Leiden University Medical Center, Leiden, The Netherlands; Centre for Molecular Medicine Norw…
  • Bone Tumor Reference Center at the Institute of Medical Genetics and Pathology, University Hospital and University of Basel, Basel, Switzerland; Basel Research Centre for Child Health, Basel, Switzerland.

Förderung

  • ZonMw
  • Leiden University Medical Center
  • Kreftforeningen
  • Universitetet i Oslo
  • Bone Cancer Research Trust
  • European Research Council
  • H2020 European Research Council
  • Norges Forskningsråd

Zitieren

APA

Meijer, D. M., Venneker, S., Ameline, B., Erdem, Z., Cardoso, S., Ruano, D., Briaire-de Bruijn, I. H., van den Akker, B. E., Wijers-Koster, P. M., Scholte, C. H. J., van Praag, V. M., van de Sande, M. A. J., Kuijjer, M. L., Baumhoer, D., de Miranda, N. F. C. C., & Bovée, J. V. M. G. (2025). An Integrated Clinical Genomic and Transcriptomic Subgrouping of Central Chondrosarcoma. Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100894

Vancouver

Meijer DM, Venneker S, Ameline B, Erdem Z, Cardoso S, Ruano D, et al. An Integrated Clinical Genomic and Transcriptomic Subgrouping of Central Chondrosarcoma. Modern Pathology. 2025. doi:10.1016/j.modpat.2025.100894

BibTeX
@article{Meijer2025,
  author = {Meijer, Debora M and Venneker, Sanne and Ameline, Baptiste and Erdem, Zeynep and Cardoso, Sara and Ruano, Dina and Briaire-de Bruijn, Inge H and van den Akker, Brendy E and Wijers-Koster, Pauline M and Scholte, Claire H J and van Praag, Veroniek M and van de Sande, Michiel A J and Kuijjer, Marieke L and Baumhoer, Daniel and de Miranda, Noel F C C and Bovée, Judith V M G},
  title = {An Integrated Clinical Genomic and Transcriptomic Subgrouping of Central Chondrosarcoma},
  journal = {Modern Pathology},
  year = {2025},
  doi = {10.1016/j.modpat.2025.100894}
}
Kostenlos starten →